Regulus Therapeutics Inc (RGLS)

2.65
0.00 (0.00)
NASDAQ : Health Care
Prev Close 2.65
Open 2.55
Day Low/High 2.42 / 2.70
52 Wk Low/High 2.44 / 10.60
Volume 375.45K
Avg Volume 436.30K
Exchange NASDAQ
Shares Outstanding 52.92M
Market Cap 150.83M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Regulus To Release Third Quarter Financial Results On November 1, 2016

Regulus To Release Third Quarter Financial Results On November 1, 2016

Conference Call and Webcast to Follow

Regulus Provides Update On Clinical Hold Of RG-101

Regulus Provides Update On Clinical Hold Of RG-101

On Track to Deliver Follow-up Results from On-going RG-101 Studies

Regulus To Release Second Quarter Financial Results On August 2, 2016

Regulus To Release Second Quarter Financial Results On August 2, 2016

Conference Call and Webcast to Follow

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Regulus Therapeutics Inc. - RGLS

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Regulus Therapeutics Inc. - RGLS

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Regulus Therapeutics Inc.

Regulus Reports Clinical Hold Of RG-101

Regulus Reports Clinical Hold Of RG-101

Timelines of On-going Studies are not Expected to be Impacted

Interesting RGLS Put And Call Options For February 2017

Interesting RGLS Put And Call Options For February 2017

Investors in Regulus Therapeutics Inc saw new options begin trading this week, for the February 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Regulus Therapeutics (RGLS): Today's Weak On High Volume Stock

Regulus Therapeutics (RGLS): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a weak on high relative volume candidate

Regulus Expands Clinical Trial Collaboration With GSK

Regulus Expands Clinical Trial Collaboration With GSK

- Phase II Study Evaluating the Combination of RG-101 and GSK's Long-Acting Parenteral (LAP) Formulation of GSK2878175 as a potential single-visit cure to begin Q4 2016

Regulus Therapeutics (RGLS): Today's Weak On High Volume Stock

Regulus Therapeutics (RGLS): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a weak on high relative volume candidate

Regulus Therapeutics (RGLS) Is Strong On High Volume Today

Regulus Therapeutics (RGLS) Is Strong On High Volume Today

Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a strong on high relative volume candidate

Interesting RGLS Put And Call Options For June 17th

Interesting RGLS Put And Call Options For June 17th

Investors in Regulus Therapeutics Inc saw new options begin trading this week, for the June 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the RGLS options chain for the new June 17th contracts and identified one put and one call contract of particular interest.

Regulus Therapeutics (RGLS) Is Weak On High Volume Today

Regulus Therapeutics (RGLS) Is Weak On High Volume Today

Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a weak on high relative volume candidate